Clinical Trials Using Daratumumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Daratumumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-49 of 49

  • A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

    The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab) and to characterize the safety of each RP2D for selected treatment combinations.
    Location: 4 locations

  • Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma in Elderly Patients

    This phase II trial studies how well daratumumab, bortezomib, lenalidomide, and dexamethasone works in treating newly diagnosed multiple myeloma in elderly patients. Daratumumab is a monoclonal antibody that may induce changes in body’s immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as bortezomib, lenalidomide, and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab, bortezomib, lenalidomide, and dexamethasone together may work better compared to bortezomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • Daratumumab, Ixazomib, and Dexamethasone with or without Bortezomib in Treating Patients with Newly Diagnosed Multiple Myeloma

    This phase II trial studies how well daratumumab, ixazomib, and dexamethasone with or without bortezomib work in treating patients with newly diagnosed multiple myeloma. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib, dexamethasone, and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving daratumumab, ixazomib, and dexamethasone with or without bortezomib may work better in treating patients with multiple myeloma.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase II trial studies how well daratumumab, bortezomib, and dexamethasone followed by daratumumab, ixazomib, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refractory). Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib and ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving daratumumab, bortezomib, and dexamethasone followed by daratumumab, ixazomib, and dexamethasone may work better and help to control cancer in patients with multiple myeloma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Daratumumab in Treating Participants with Relapsed Multiple Myeloma after Stem Cell Transplant

    This phase II trial studies how well daratumumab works in treating participants with multiple myeloma that has come back after stem cell transplant. Immunotherapy with daratumumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Daratumumab and Donor Lymphocyte Infusion in Treating Patients with Relapsed Acute Myeloid Leukemia after Stem Cell Transplant

    This phase I / II trial studies the side effects and best dose of donor lymphocyte infusions when given together with daratumumab and to see how well they work in treating patients with acute myeloid leukemia that has come back (relapsed) after a stem cell transplant. A donor lymphocyte infusion is a type of therapy in which lymphocytes (white blood cells) from the blood of a donor are given to a participant who has already received a stem cell transplant from the same donor. The donor lymphocytes may kill remaining cancer cells. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Giving daratumumab and donor white blood cells may work better in treating patients with acute myeloid leukemia.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Daratumumab, Carfilzomib, Lenalidomide, and Low-dose Dexamethasone in Treating Participants with Newly-diagnosed, Multiple Myeloma

    This phase II trial studies how well daratumumab, carfilzomib, lenalidomide, and low-dose dexamethasone work in treating participants with newly-diagnosed multiple myeloma. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Carfilzomib may stop the growth of tumor cells by blocking some of the enzymes need for cell growth. Drugs used in chemotherapy, such as lenalidomide and low-dose dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab, carfilzomib, lenalidomide, and low-dose dexamethasone may work better in treating participants with newly-diagnosed multiple myeloma.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

    This is an open-label Phase 1 / 2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma following 1-4 lines of prior therapy. Patients will receive either melflufen+dexamethasone+bortezomib or melflufen+dexamethasone+daratumumab and are required to be IMiD refractory to be enrolled to the bortezomib regimen, and to not have any prior exposure to daratumumab or other antiCD-38 mAb to be enrolled to the daratumumab regimen.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Daratumumab in Treating Transplant-Eligible Patients with Multiple Myeloma

    This phase II trial studies how well daratumumab works in treating transplant-eligible patients with multiple myeloma. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
    Location: Mayo Clinic in Florida, Jacksonville, Florida

  • Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

    This pilot early phase I trial studies the side effects of daratumumab and to see how well it works in treating patients with muscle invasive bladder cancer or kidney cancer that has spread to other places in the body. Immunotherapy with daratumumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Daratumumab and Ibrutinib in Treating Patients with Symptomatic Chronic Lymphocytic Leukemia

    This phase Ib trials studies the side effects of daratumumab and ibrutinib and how well they work in treating patients with symptomatic chronic lymphocytic leukemia. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving daratumumab and ibrutinib may work better in treating patients with chronic lymphocytic leukemia.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Daratumumab after Stem Cell Transplant in Treating Patients with Multiple Myeloma

    This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
    Location: 2 locations

  • Daratumumab in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia, T Acute Lymphoblastic Leukemia / Lymphoma, or High-Risk Myelodysplastic Syndrome

    This phase II trial studies how well daratumumab works in treating patients with acute myeloid leukemia or T acute lymphoblastic leukemia / lymphoma that has come back or does not respond to treatment or high-risk myelodysplastic syndrome. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery (Part 1) and CF (co-formulated daratumumab and rHuPH20 preparation) administration via SC delivery of daratumumab (Part 2) and to evaluate the safety of Dara-CF 1800 milligram (mg) SC delivery without pre-dose and post-dose corticosteroids (Part 3).
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

    This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of lenalidomide-based therapy. This trial will test the hypothesis for Cohort A that the proportion of patients will have an Overall Response Rate (ORR) of > 30 % to reveal that Pomalidomide is efficacious in pretreated patients who are refractory to lenalidomide. This trial will test the hypothesis for Cohort B that the proportion of patients will have an Overall Response Rate (ORR) of > 70 % to reveal that POM+DARA+LD-Dex is efficacious in pretreated patients who are refractory to lenalidomide. This trial will test the hypothesis for Cohort C that the proportion of patients will have an Overall Response Rate (ORR) of >60% to reveal that POM+DARA+LD-Dex is efficacious in pretreated patients who are refractory to lenalidomide. This treatment will be in only Japanese patients.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed / Refractory Multiple Myeloma

    This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib / dexamethasone (Arm A) versus daratumumab in combination with bortezomib / dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
    Location: 2 locations

  • Study of Lenalidomide / Ixazomib / Dexamethasone / Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

    A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with lenalidomide, ixazomib, dexamethasone, and daratumumab. Patients will be randomized to either: Arm A: 12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy. Arm B: 12 cycles of lenalidomide, ixazomib, daratumumab and dexamethasone, followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 years maintenance therapy.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Frailty Score-Guided Dosing of Lenalidomide, Dexamethasone, and Daratumumab for the Treatment of Multiple Myeloma, MMY2035 Study

    This phase II trial studies the side effects and how well frailty score-guided dosing of lenalidomide with dexamethasone and daratumumab work for the treatment of multiple myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with daratumumab, may induce changes in body’s immune system and may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide at a reduced dose, and increasing the dose as it is tolerated, with dexamethasone and daratumumab may work better in controlling cancer without causing serious side effects and allow patients to say on treatment for a longer period.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

    This phase II trial studies how well a reduced intensity conditioning regimen after donor stem cell transplant works in treating patients with multiple myeloma that has come back (relapsed). Drugs used in chemotherapy, such as cyclophosphamide, tacrolimus, and mycophenolate mofetil, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving a reduced intensity conditioning regimen consisting of cyclophosphamide, tacrolimus, mycophenolate mofetil, and daratumumab after donor stem cell transplant may improve survival and reduce the risk of multiple myeloma coming back.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Escalation of Daratumumab Frequency for the Treatment of Relapsed or Refractory Multiple Myeloma

    This phase II trial studies how well escalation of daratumumab frequency works for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Daratumumab is an antibody designed to specifically target and eliminate a specific harmful object in your body, in this case cancerous plasma cells.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

    This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with daratumumab may induce changes in body’s immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab with dexamethasone and pomalidomide may work bettering in treating patient compared to dexamethasone and pomalidomide alone.
    Location: 5 locations

  • Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

    This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. Injecting tiny amounts of anti-cancer drugs directly into tumors on the skin or in lymph nodes and diagnostic procedures, such as FDG-PET, may help to show which drugs work better in treating patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.
    Location: Mayo Clinic, Rochester, Minnesota

  • Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients with Relapsed Multiple Myeloma

    This pilot phase I trial studies how well copper 64Cu-tetraxetan (DOTA)-daratumumab positron emission tomography works in diagnosing patients with multiple myeloma that has come back. Diagnostic procedures, such as copper 64Cu-DOTA-daratumumab positron emission tomography, may help evaluate the extent of multiple myeloma in patients prior to the initiation of treatment and ultimately monitor disease status / response during and post treatment.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California